← Browse by Condition
Medical Condition
multiple myeloma in relapse
Total Trials
7
Recruiting Now
7
Trial Phases
Phase 1, EARLY_Phase 1, Phase 2
ClinicalMetric tracks all active clinical trials for multiple myeloma in relapse sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.
Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.
Frequently Asked Questions — multiple myeloma in relapse Clinical Trials
How many clinical trials are currently recruiting for multiple myeloma in relapse?
ClinicalMetric currently tracks 7 actively recruiting clinical trials for multiple myeloma in relapse, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 7. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for multiple myeloma in relapse?
multiple myeloma in relapse research spans Phase 1 (5 trials), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a multiple myeloma in relapse clinical trial?
Eligibility criteria for multiple myeloma in relapse trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 5
Phase 2 2
Top Sponsors
2 trials
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT07075185 Phase 1
Recruiting
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Enrollment
70 pts
Location
United States, Austr...
Sponsor
Kelonia Therapeutics, Inc.
NCT05020444 Phase 1
Recruiting
TriPRIL CAR T Cells in Multiple Myeloma
Enrollment
18 pts
Location
United States
Sponsor
Marcela V. Maus, M.D.,Ph.D.
NCT04657861 EARLY_Phase 1
Recruiting
APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma
Enrollment
36 pts
Location
China
Sponsor
Zhejiang University
NCT04603872 EARLY_Phase 1
Recruiting
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
Enrollment
120 pts
Location
China
Sponsor
Zhejiang University
NCT06115135 Phase 2
Recruiting
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Enrollment
39 pts
Location
United States
Sponsor
Oncotherapeutics
NCT04176718 Phase 2
Recruiting
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Enrollment
43 pts
Location
United States
Sponsor
Andrew Yee, MD
NCT05546723 Phase 1
Recruiting
LMY-920 for Treatment of Relapsed or Refractory Myeloma
Enrollment
30 pts
Location
United States
Sponsor
Luminary Therapeutics
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology